These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65. Deciphering the Potential Role of Specialized Pro-Resolving Mediators in Obesity-Associated Metabolic Disorders. Kim N; Shin HY Int J Mol Sci; 2024 Sep; 25(17):. PubMed ID: 39273541 [TBL] [Abstract][Full Text] [Related]
66. Biomimetic Nanocarriers of Pro-Resolving Lipid Mediators for Resolution of Inflammation in Atherosclerosis. Anghelache M; Voicu G; Deleanu M; Turtoi M; Safciuc F; Anton R; Boteanu D; Fenyo IM; Manduteanu I; Simionescu M; Calin M Adv Healthc Mater; 2024 Jan; 13(3):e2302238. PubMed ID: 37852632 [TBL] [Abstract][Full Text] [Related]
67. Lipoxins and new lipid mediators in the resolution of inflammation. Schwab JM; Serhan CN Curr Opin Pharmacol; 2006 Aug; 6(4):414-20. PubMed ID: 16750421 [TBL] [Abstract][Full Text] [Related]
68. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Bannenberg G; Serhan CN Biochim Biophys Acta; 2010 Dec; 1801(12):1260-73. PubMed ID: 20708099 [TBL] [Abstract][Full Text] [Related]
69. Deciphering the role of n-3 polyunsaturated fatty acid-derived lipid mediators in health and disease. Spite M Proc Nutr Soc; 2013 Nov; 72(4):441-50. PubMed ID: 23991833 [TBL] [Abstract][Full Text] [Related]
70. From Inflammation to Resolution: Specialized Pro-resolving Mediators in Posttraumatic Osteoarthritis. Leite CBG; Merkely G; Charles JF; Lattermann C Curr Osteoporos Rep; 2023 Dec; 21(6):758-770. PubMed ID: 37615856 [TBL] [Abstract][Full Text] [Related]
71. Anti-Inflammatory Function of Fatty Acids and Involvement of Their Metabolites in the Resolution of Inflammation in Chronic Obstructive Pulmonary Disease. Kotlyarov S; Kotlyarova A Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884621 [TBL] [Abstract][Full Text] [Related]
72. Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. Serhan CN Annu Rev Immunol; 2007; 25():101-37. PubMed ID: 17090225 [TBL] [Abstract][Full Text] [Related]
73. Towards targeting resolution pathways of airway inflammation in asthma. Barnig C; Frossard N; Levy BD Pharmacol Ther; 2018 Jun; 186():98-113. PubMed ID: 29352860 [TBL] [Abstract][Full Text] [Related]
74. Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis. Philippe R; Urbach V Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30241412 [TBL] [Abstract][Full Text] [Related]
75. Pro-Resolving Molecules-New Approaches to Treat Sepsis? Buechler C; Pohl R; Aslanidis C Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28241480 [TBL] [Abstract][Full Text] [Related]
77. Development and Validation of Methodologies for the Identification of Specialized Pro-Resolving Lipid Mediators and Classic Eicosanoids in Biological Matrices. Dooley M; Saliani A; Dalli J J Am Soc Mass Spectrom; 2024 Oct; 35(10):2331-2343. PubMed ID: 39252416 [TBL] [Abstract][Full Text] [Related]
78. Cyclopentenone-containing oxidized phospholipids and their isoprostanes as pro-resolving mediators of inflammation. Friedli O; Freigang S Biochim Biophys Acta Mol Cell Biol Lipids; 2017 Apr; 1862(4):382-392. PubMed ID: 27422370 [TBL] [Abstract][Full Text] [Related]
79. Identification and Profiling of Specialized Pro-Resolving Mediators in Human Tears by Lipid Mediator Metabolomics. English JT; Norris PC; Hodges RR; Dartt DA; Serhan CN Prostaglandins Leukot Essent Fatty Acids; 2017 Feb; 117():17-27. PubMed ID: 28237084 [TBL] [Abstract][Full Text] [Related]
80. Eicosapentaenoic and docosahexaenoic acid derived specialised pro-resolving mediators: Concentrations in humans and the effects of age, sex, disease and increased omega-3 fatty acid intake. Calder PC Biochimie; 2020 Nov; 178():105-123. PubMed ID: 32860894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]